Drug therapy in anticoagulation: which drug for which patient?
Open accessThe DOI matches its Crossref record, with a small difference in title or year; the references it cites are not checked yet.
Abstract
Four non-vitamin K oral anticoagulants (NOACs) are now licensed and available in the UK, offering unprecedented choices in anticoagulant therapy for clinicians and patients. NOACs have many clear benefits over warfarin, the most striking being the reduction in intracranial haemorrhage. However, a number of uncertainties remain: their efficacy in certain situations, utility of drug assays, significance of drug interactions and management of bleeding. In the absence of any direct comparative trials, it is not clear that any of the NOACs is significantly better than the others in any of the licensed indications. The differential activities, pharmacokinetics, metabolism, excretion and side effects of the agents should be considered when selecting the most appropriate anticoagulant. In this article, we discuss how, with careful selection for the relevant indication, NOACs can simplify therapy while improving outcomes. We aim to provide clinicians with the information needed to select the most suitable anticoagulant drug for an individual patient in a given situation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the 4 agents that are currently available differ in the proportion of drug that is cleared by the kidneys, ranging from ; 80%for dabigatran to 25% for apixaban. 118”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [118]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 86 · Cited by 11
Metadata
- Authors
- Millar, C. M., & Laffan, M. A.
- Affiliations
- Imperial College Healthcare NHS Trust (GB)
- Corresponding author
- Millar, Carolyn M
- Venue
- Clinical Medicine
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 17
- Issue
- 3
- Pages
- 233-244
- ISSN
- 1470-2118 (ISSN-L)
- PMC
- PMC6297571
- OpenAlex
- W2617874505
- Cited by
- 11
- References
- 86
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 2 · 2022: 1 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 1
- FWCI
- 1.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 2498 d)
- Locations
- Clinical Medicine (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- National Institute for Health and Care Research
- Imperial College London
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- direct oral anticoagulants, anticoagulant selection, warfarin, intracranial hemorrhage, drug interactions, hemorrhage control, anticoagulation monitoring, pharmacokinetics, thromboprophylaxis
- MeSH terms
- Aged, Aged, 80 and over, Anticoagulants, Antithrombins, Atrial Fibrillation, Humans, Comorbidity, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug therapy in anticoagulation: which drug for which patient? https://app.cochat.ai/papers/10.7861/clinmedicine.17-3-233
- The paper
- Millar, C. M., & Laffan, M. A. (2017). Drug therapy in anticoagulation: which drug for which patient? Clinical Medicine. https://doi.org/10.7861/clinmedicine.17-3-233
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.